Investing.com – Acer Therapeutics on Monday reported third-quarter revenue that beat analysts’ forecasts and revenue that was in line with expectations.
Acer Therapeutics announced earnings per share of $-0.310 on revenue of $0.00. Analysts polled by Investing.com were expecting EPS of $-0.755 on revenue of $0.00.
Acer Therapeutics shares are down 30% year-to-date and are trading at $1.200, down from a 52-week high.
Acer Therapeutics follows another big earner in the Healthcare sector this month
Acer Therapeutics’ report follows the earnings beat by J&J on Tuesday, October 18, 2022, reported EPS of $2.55 on revenue of $23.79B, compared to EPS forecasts of $2.48 on revenue of $23.36B.
Eli Lilly It beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, compared to the forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar